INTRODUCTION
FLT3 is a member of the class III receptor tyrosine kinase (TK) family that is expressed on the cell membrane of most AML blast progenitor cells (BPCs) (1,2). Interaction with FLT3 ligand causes homodimerization, auto-phosphorylation and activation of FLT3 (1,2). Activated FLT3 transduces pro-growth and pro-survival signaling through STAT5, PI3K/AKT and RAS/RAF/ERK1/2 pathways (2,3).
Activating, somatic, gain-of-function FLT3 internal tandem duplication (ITD) mutations and FLT3-TK domain (TKD) mutations are observed in approximately 25% and 8% of AML, respectively (2, 3) . In addition to FLT3-TKD-D835V/Y, other mutations within the TKD have also been reported (4) . Several FLT3 kinase inhibitors (FLT3-TKI) have been clinically tested but none is yet approved for the therapy of AML (5, 6) . Although treatment with FLT3-TKI has been documented to induce clinical remissions, emergence of resistance that prevents durable remissions and limits leukemia-free survival remains a challenge (6) . While approved for BCR-ABL TKI resistant CML, ponatinib has also been shown to potently inhibit FLT3 and its downstream signaling and exert preclinical and clinical activity against AML expressing FLT3-ITD (6, 7) . AC220 (quizartinib) is a highly active FLT3-TKI, which induces terminal myeloid differentiation in vivo and is currently being evaluated for efficacy in clinical trials (6, (8) (9) (10) . Recently, ponatinib was shown to be active against AC220-resistant kinase domain mutants of AML expressing FLT3-ITD (6, 11) . Several studies have documented the mechanisms of resistance to FLT-TKI in AML blasts expressing FLT3 mutation (2, 4, 6, (12) (13) (14) (15) . These include the acquisition of secondary FLT3-TKD mutations: the gatekeeper F691I/L in the TKD1 of the ATP binding pocket, the D835V/Y/F in the activation loop of TKD2, and the compound FLT3-ITD/F691I mutation (4, 6, 14) .
FLT3-TKI resistance may also be due to amplification of the FLT3 locus on chromosome 13 with overexpression of FLT3-ITD protein (2) . Recently, increased FL expression with up regulation of STAT3 activity and survivin levels has been noted in AML blasts demonstrating resistance to FLT3-TKI that otherwise did not exhibit mutations in FLT3-TKD (15) (16) (17) . Levels of FL have been demonstrated to rise during treatment of AML with chemotherapy, and FLT3 ligand was shown to impede the in vitro and in vivo efficacy of FLT3-TKI (15) (16) (17) . Thus, the autocrine induction of FL may mediate activation of FLT3-ITD and confer clinical resistance to FLT3-TKIs (15) (16) (17) . Finally, increase in the activity of the compensatory and collateral pro-growth and pro-survival signaling pathways and up regulation of antiapoptotic proteins may also confer resistance to FLT3-TKI treatment (2, 6, 13) . Collectively, these observations underscore the need to develop and test novel agents and combinations that are more effective, as well as overcome resistance to FLT3-TKI in AML blast progenitor cells.
The family of BET (bromodomain and extraterminal) proteins, including BRD4, are chromatin 'reader' proteins that contain the N-terminal double, tandem, 110 amino acids-long bromodomains, through which they bind to the acetylated lysines on histone proteins (18, 19) . Through their extra-terminal (ET) protein-interacting domain in the C-terminus, BET proteins recruit co-regulatory complexes containing chromatin-modifying enzymes, chromatin remodeling factors and the mediator elements to the chromatin for regulating gene transcription (19) (20) (21) . The C-terminal domain (CTD) of BRD4 interacts with pTEFb (positive transcription elongation factor b), the heterodimer composed of cyclin T and CDK9, which phosphorylates serine 2 on the CTD of RNA pol II (RNAP2) causing its pause release and mRNA transcript elongation (20) (21) (22) (23) . Recently, an RNAi screen identified BRD4 as an effective and promising target in human AML (24). Several structure/activity-based BET protein small molecule 4 inhibitors have been developed, e.g., JQ1 and I-BET151 (25,26). Treatment with JQ1 disrupts the binding of the bromodomains of BRD4 to acetylated lysines, displacing the BET proteins, along with the associated transcript initiation and elongation factors from the enhancers and promoters of several oncogenes, including c-MYC, BCL2 and CDK6. (21, 25, 27) . Recently, JQ1 was demonstrated to deplete the binding of BRD4, mediator and pTEFb to the clusters of enhancers called the 'super enhancers' of some oncogenes such as c-MYC, CDK6 and BCL2. This was associated with the depletion of their transcript levels (21, (27) (28) (29) . JQ1 treatment also induces hexamethylene-bis-acetamide (HMBA)-inducible protein 1 (HEXIM1), which binds to cyclin T and sequesters pTEFb in an inhibitory complex that also includes the non-coding 7SK RNA (30,31). This reduces the available kinase activity of pTEFb for phosphorylating and inducing the pause release of RNAP2, thereby contributing to the inhibition of the mRNA transcript elongation and expression of the oncogenes (21, 23, 28) . Collectively, JQ1 mediated inhibitory effects on the oncogene transcription are associated with growth inhibition and apoptosis of AML cells (32-35). This has been especially noted for AML cells expressing the mutant NPM1 (NPM1c+) or Mixed Lineage Leukemia (MLL) containing fusion oncoproteins, with or without the expression of FLT3-ITD (33-35). We also previously reported that co-treatment with JQ1 and the pan-histone deacetylase (HDAC) inhibitor (HDI) panobinostat (PS), exerts synergistic lethality against the cultured and primary AML BPCs expressing FLT3-ITD (34). In the present studies, we demonstrate that co-treatment with JQ1 and the FLT3-TKIs ponatinib or quizartinib is synergistically lethal against human cultured or primary AML blast progenitor cells (BPCs) expressing FLT3-ITD. The combination concomitantly further attenuates the levels of pro-growth and pro-survival proteins e.g., c-MYC, BCL2 and CDK4/6, while simultaneously inducing the levels of p21, HEXIM1 and the pro-apoptotic protein BIM. Finally, JQ1 alone or in combination with PS was highly active against FLT3-TKI resistant AML cells (FLT3-TKIR) expressing FLT3-ITD.
MATERIALS AND METHODS
Reagents: (S)-JQ1 (active enantiomer, hereafter referred to as JQ1) was developed as previously described (25). I-BET151 and ABT-199 were obtained from Xcess Biologicals (San Diego, CA). Technologies catalog no. 4474006). A total of 1.88 million (M) and 3.15 M mapped reads were obtained for the MOLM13 and MOLM13-TKIR samples, respectively. Sequences were aligned to the abovespecified targeted regions of human genome (hg)19 using ion-alignment v3.6.56201 software, and variant analysis was done with VariantCaller v3.6.63335 software using the "Somatic -Low Stringency" parameter setting.
Primary normal progenitor and AML BPCs: Primary peripheral blood and/or bone marrow aspirate AML samples were obtained and prepared for the studies below, as previously described (37,38).
Banked, de-linked and de-identified, normal or AML CD34+ bone marrow progenitor/stem cells were purified, as previously described (38). The clinical presentation of the patient and mutation status of the primary AML samples utilized in these studies is provided in Supplemental Table 1 Cell lysis, protein quantitation and immunoblot analyses: Untreated or drug-treated cells were centrifuged, and the cell pellets were lysed and the protein quantitation and immunoblot analyses were performed, as previously described (34,40). Immunoblot analyses were performed at least twice. The expression levels of β-Actin served as the loading control. Representative immunoblots were subjected to densitometry analysis. Densitometry was performed using ImageQuant 5.2 (GE Healthcare, Piscataway, NJ).
Statistical Analysis: Significant differences between values obtained in a population of AML cells treated with different experimental conditions were determined using a two-tailed, paired t-test or a one way ANOVA analysis within an analysis package of Microsoft Excel 2010 software or using GraphPad Prism (GraphPad Software, Inc., CA). P values of less than 0.05 were assigned significance. Figure 2G ). Co-treatment with JQ1 and quizartinib also resulted in greater inhibition of the levels of p-STAT5, p-AKT and p-ERK1/2 without significant alterations in the un-phosphorylated versions of these proteins ( Figure 1D ). Treatment with JQ1, but not quzartinib, also markedly induced the levels of HEXIM1 which was slightly inhibited by co-treatment with quzartinib ( Figure 1C ). Figure   2A demonstrates that co-treatment with JQ1 and ponatinib also induced significantly more apoptosis of Figure 3A demonstrates that, although, the loss of viability in the primary AML progenitor cells was lower than in the cultured AML cell types, exposure to 250 nM JQ1 exerted greater lethal effects than exposure to 100 nM of ponatinib. Co-treatment with JQ1 and ponatinib was more lethal than each agent alone against the primary AML BPCs ( Figure 3A ).
RESULTS
Importantly, combined treatment with JQ1 and ponatinib exerted significantly greater lethality against the primary AML versus normal progenitor cells ( Figure 3A) . Additionally, co-treatment with JQ1 and ponatinib or quizartinib was synergistically lethal against primary AML BPCs, showing combination indices of less than 1.0 ( Figure 3B and 3C). This synergy was observed whether FLT3-ITD was expressed alone or with additional mutation such as NPM1c+ (Supplemental Figure 5A and 5B). Cotreatment with JQ1 and ponatinib or quizartinib was synergistically lethal, regardless of the coexpression of FLT3-ITD with or without NPM1c+ (Supplemental Figure 5C and data not shown). As Figure 5A and 5B), although MOLM13-TKIR cells displayed higher % of cells in the S phase of the cell cycle ( Figure 5C ). Importantly, MOLM13-TKIR cells had significantly higher IC 50 values for quizartinib and ponatinib, (>1000 nM and 674.6 nM respectively), as compared to the parental MOLM13 cells (13.46 nM and 13.96 nM respectively) (Supplemental Table 2 ). Next generation sequencing (NGS) of the 23 exons of FLT3 in the MOLM13-TKIR cells did not reveal any mutation in FLT3 that has been previously discovered and reported following in vitro or in vivo exposure to FLT3-TKIs, including quizartinib or ponatinib (2, 4, 6, 14) . However, we did detect a very low allelic frequency mutation in FLT3 represented by the Table 2 ). The observed collateral sensitivity of MOLM13-TKIR cells to JQ1 was associated with greater induction of p21, HEXIM1, BIM and cleaved PARP by JQ1 treatment in MOLM13-TKIR versus MOLM13 cells. We next determined whether the combination of JQ1 with AC220 would exert greater anti-leukemia activity against the MOLM13-TKIR cells. In contrast to the synergistic anti-leukemia activity of JQ1 and AC220 in MOLM13 cells, the combination of JQ1 and AC220 was no more effective than treatment with JQ1 alone in the MOLM13-TKIR cells (Supplemental Figure 7A also demonstrates that treatment with JQ1 alone dosedependently, but modestly, attenuated the levels of HDAC1, HDAC2, HDAC3, EZH2 and SUZ12, without affecting the levels of HDAC6. We had also previously reported that combined therapy with JQ1 and PS exerts synergistic lethality against cultured and primary human AML BPCs, including those expressing FLT3-ITD such as MOLM13 cells (34). Collectively, based on this, in the present studies we determined the activity of JQ1 and PS against FLT3-TKI resistant MOLM13-TKIR cells. As compared to each agent alone, combined treatment with JQ1 and PS induced significantly more apoptosis of MOLM13-TKIR cells ( Figure 7B ). Furthermore, Figure 7C demonstrates that co-treatment with PS and JQ1 synergistically induced apoptosis of MOLM13-TKIR cells, with combination indices of less than 1.0 by the median dose effect and isobologram analyses. This synergistic effect of the combination was associated with greater decline in c-MYC, CDK4/6 and Bcl-x L , as well as greater induction of the levels of HEXIM1 and p21 ( Figure 7D ). Co-treatment with JQ1 and PS was also synergistically lethal against quizartinib-resistant MV4-11-TKIR cells that were approximately 10-fold resistant to quizartinib, and were isolated in a manner similar to MOLM13-TKIR cells (Supplemental Figure 9) . We had previously confirmed the specific activity of JQ1 in this synergistic interaction by demonstrating that co-treatment with (R)-JQ1 did not enhance PS-induced apoptosis in MOLM13 cells (34).
DISCUSSION
The FLT3-TKIs quizartinib and ponatinib are potent type II FLT3 antagonists that bind and inhibit the inactive conformation of FLT3-TK where the activation loop is in the DFG 'out' position (4,6).
Although they inhibit growth and induce differentiation and apoptosis, as well as induce complete remission in patients with AML, following treatment with the FLT3-TKI, relapse, due to residual AML in which FLT3-ITD activity is persistent, is commonly encountered (2, 4, 6, 14) . Several mechanisms of primary resistance to FLT3-TKI have been described in AML BPCs expressing FLT3-ITD. These include the protective effects of stromal niche cells (41), increased levels and activity of FLT3 ligand on FLT3 TK (15, 17) , trans-phosphorylation and increased activity of FLT3 by other kinases such as PIM-1 and SYK (42, 43) , and the collateral dependency on other important pro-growth and pro-survival signaling mechanisms (5, 6, 12, 13) . Other studies have focused on developing selective and more potent FLT3-TKI to overcome primary resistance to the first and second generation FLT3-TKI already in the clinic (44, 45) . Here, we document for the first time that co-treatment with the BET protein antagonist shown to inhibit p-STAT5 and be active against myeloid malignancies (46) . It is noteworthy that whereas the genetic knockdown of BRD4 enhanced the anti-AML lethality of quizartinib or ponatinib, this effect was less pronounced than the effect of BRD4 inhibition by co-treatment with JQ1, which mediates its growth inhibitory and lethal effects by inhibiting BET proteins in addition to BRD4.
Collectively, these data highlight the promise of including a BET protein antagonist in combination with quizartinib or ponatinib for the treatment of high-risk AML expressing FLT3-ITD. 
